Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Immunex Enbrel Sales Capped At $800 Mil. With Current Production Capacity

Executive Summary

Sales of Immunex' rheumatoid arthritis drug Enbrel (etanercept) in the U.S. are capped at $800 mil. a year at the current manufacturing capacity, Immunex said in an Aug. 9 Securities & Exchange Commission filing.

You may also be interested in...



Biopharma Protein Shortages Will Be Addressed By Supplier Alliances - Lilly

Biopharmaceutical manufacturing alliances will be on the rise over the next two to three years as companies address the expected shortfall in protein supply, Lilly Fermentation and Cell Culture Process Development Head Morris Rosenberg predicted.

Biopharma Protein Shortages Will Be Addressed By Supplier Alliances - Lilly

Biopharmaceutical manufacturing alliances will be on the rise over the next two to three years as companies address the expected shortfall in protein supply, Lilly Fermentation and Cell Culture Process Development Head Morris Rosenberg predicted.

Enbrel Sales Near Production Cap; New Plant To Produce Clinical Lots In 2001

Immunex will use its newly acquired Rhode Island production facility to supply Enbrel (etanercept) for clinical trials during 2001.

Related Content

UsernamePublicRestriction

Register

PS036493

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel